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ABSTRACT 
As more studies accumulate on the impact of diabetes mellitus on the central nervous 
system, they resound with the same conclusion - diabetes has a detrimental effect on cognition 
regardless of the presence of comorbidities. Less consistent however, are the specific mental 
processes wherein these declines are noticeable, and the structural changes that accompany these 
reductions in mental capacity. From global atrophy to changes in the volume of gray and white 
matter, to conflicting results regarding the effects of hypo- and hyperglycemic states on the 
development of the hippocampus, the studies display a variety of results. The goal of this 
research is to link the structural and compositional changes occurring in the diabetic brain with 
the clinical and behavioral findings highlighted in the literature, as well as to explore the 
potential mechanisms behind the pathologic brain state of diabetic encephalopathy.  
Using diabetic (OVE26) and non-diabetic wild type (FVB) mice as models, differences in 
the number of hippocampal neurons in the dentate gyrus, and cornu ammonis areas 1,2, and 3 
were investigated through Nissl staining. Neurodegeneration was confirmed in those cells 
determined to be hyperchromatic in the diabetic model through staining with Fluoro-Jade C. 
Finally, the presence of progenitor cells in the hippocampus was compared in the diabetic and 
non-diabetic models using Musashi-1 antibodies, to determine whether neurogenesis in these 
areas is affected by diabetes. These experiments were performed to better understand the effect 
of DM on learning and memory, and could potentially explain the linkage between diabetes 
mellitus and the increased prevalence of Alzheimer’s disease, vascular dementia, and depression 
in this subset of the population. 
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INTRODUCTION 
Diabetes mellitus is a disease wherein glucose uptake from the bloodstream into cells is 
inhibited, leading to retinopathy, nephropathy, vasculopathy, and disturbances of the autonomic 
nervous system.1 Moreover, diabetes has been shown to have significant effects on cognition 
through neural structural changes; therefore the focus of our study was to determine the effects 
of diabetes mellitus on the brain. Evidence suggests that both type I and type II diabetics have an 
increased risk of acquiring vascular dementia and Alzheimer’s disease, and a greater chance of 
suffering cognitive impairments.2 Cognitive decline is also more likely to occur by 60-100% if 
an individual with diabetes has chronic hyperglycemia.3 The decline is characterized by “neural 
slowing, attention deficit, and [difficulties in] executive functioning,” and type I diabetics were 
shown to have lower verbal and overall IQ scores in bouts of acute hyperglycemia in which 
blood glucose concentrations were above 15 mM.3 This may be due to a regulatory mechanism 
found in type I diabetic patients, but not in their type II counterparts, in which cerebral blood 
flow increased during periods of hypoglycemia and decreased during periods of hyperglycemia.2 
Possibly akin to the way in which cerebral blood flow is increased in cases of chronic hypoxia, 
or hypercapnia, by affecting capillary density and vasodilating blood vessels, the opposite effect 
may be taking place in the brain when blood glucose concentration is too high.4 Moreover, 
decreased cerebral blood flow has been linked to total brain volume atrophy in Voxel-based 
morphometry studies, and arterial spin labeling MRI studies confirm this by showing evidence of 
cortical and subcortical atrophy.3, 5  
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In type II diabetics, on the other hand, hippocampal atrophy associated with memory 
impairment is more prominent, which may be due to the fact that the onset of type II diabetes 
often occurs in older patients.3 Since type II diabetes is caused by insulin insensitivity, 
hippocampal atrophy may be explained by the fact that insulin prevents the binding of 
pathogenic Aβ oligomers to “sites localized at hippocampal nerve cell synapses,” and if proper 
insulin binding cannot occur, this CNS protection is no longer present.5 Extended episodes of 
severe hypoglycemia are also known to cause the direct necrosis of these neurons.3 Of the areas 
most severely affected, the limbic unci and cerebellar posterior lobe, structures associated with 
language, affect, and executive function, are linked to the greatest loss of gray matter density.3 
Voxel-based morphometry also revealed some of the more subtle structural changes that occur at 
the earlier stages of type II diabetes, which included “global brain volume atrophy, hippocampal 
and amygdala atrophy, and gray and white matter atrophy in the right temporal lobe.”5 The 
subsequent cognitive dysfunction and dementia that was observed in tandem was accounted to 
cerebral hypoperfusion, since perfusion is one of the main indicators utilized in measuring tissue 
function.5 While this decrease in perfusion was observed in type II patients, in rodent studies 
involving Streptozotocin-injected animals, which simulate the type I diabetic model via toxic 
destruction of pancreatic β-cells, the number of BBB tight junction proteins decreased, thereby 
increasing the permeability and perfusion of the blood brain barrier.2, 6 On the whole, the 
structural and neurophysiological modifications that have been found in the brains of type I and 
type II diabetic patients are significant enough to be considered a diabetic encephalopathy 
because of the cognitive deficits incurred as a result.7 The overall progression of the disease has 
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been succinctly summarized as “accelerated brain aging,” and both hypoglycemic and 
hyperglycemic episodes have been the suspected causes in varying studies.5, 8 
 The purpose of this research was to determine whether signs of neurodegeneration, as 
well as disturbed neurogenesis were present in diabetic versus wild type mice, as a model of 
potential findings for this disease state in humans. According to one study wherein hippocampal 
neurogenesis was impaired via irradiation, the mice later showed deficits in retention of spatial 
memory, and overall reduced cognition.9 Even age-related reductions in the ability to generate 
new neurons in the hippocampus have been implicated as the source of impaired learning.10 
Therefore, we carried out a series of experiments using frozen leftover brain tissues from OVE26 
(diabetic) and FVB (wild type) mice from Dr. Cheng’s prior experiments, to see whether these 
patterns of increased neurodegeneration and decreased neurogenesis were present. 
 The OVE26 mice that were used in these experiments are transgenic variants of the FVB 
mice, and portray an early type I diabetic model.11 The insulin calmodulin gene in these mice is 
overexpressed, resulting in β cell toxicity that is sufficient enough to induce type I diabetes, but 
allows a small proportion of cells to survive so that the mouse can live for at least a year without 
insulin treatment.11 In addition to type I diabetes, these mice typically display characteristics 
such as decreased glomerular filtration rate, hypoalbuminemia, and high blood pressure as 
complications of their underlying condition.11 
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MATERIALS AND METHODS 
 The specific aims of this research were as follows: 1) to determine changes in 
neurodegeneration between diabetic and nondiabetic mice in the dentate gyrus, CA1, CA2, and 
CA3 regions of the hippocampus by means of histological analysis, and 2) to determine whether 
there were marked differences in the level of neurogenesis occurring in the tissues of diabetic 
and normal mice. The tissues obtained for staining and experimentation were donated by Dr. 
Cheng’s lab as leftover frozen specimens from previous experiments. They used the procedure 
below for perfusing the mice, removing the brain, and preserving the tissues, prior to storage in a 
-80°C freezer for two to three years (IACUC 15-19). 
Method for Perfusion, Removal, and Preservation of Mouse Tissues 
1. Three-month old FVB (wild type normal) and OVE26 (diabetic) mice were injected with 
a sub-lethal dose of sodium pentobarbital (i.p.,100ug/g) sufficient to induce deep 
anesthesia. Suitable depth of anesthesia was determined by the absence of the hind-paw 
pinch withdrawal reflex. 
2. An incision was made bilaterally from the tip of the sternum to the axillary region of the 
mouse, and the flap of skin was gently removed upwards to expose the ribcage. 
3. The tip of the sternum was lifted using a small pair of forceps, and an incision was made 
near the base of the sternum and continued along the base of the ribcage toward the spine 
on both sides, stopping approximately 2 centimeters short of the spine. 
4. The tip of the sternum was clamped with a small pair of hemostats, and the rib cage was 
cut bilaterally approximately 1.5 cm from the midline towards the clavicle.  The central 
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part of the ribcage was then lifted and held out of the way by weight of the hemostat to 
expose the heart and lungs. 
5. 0.1 mL heparin solution was injected into the left ventricle, and the animal was left alone 
for 1 minute to allow heparin to circulate.  The thoracic cavity was kept moist with warm 
PBS during this procedure. 
6. While the heart was still beating, a 22-guage needle was inserted into the left ventricle 
and stabilized in position using a hemostat.  The inferior vena cava was then located and 
cut, opening the circulatory system for drainage.  Warm PBS was then introduced into the 
circulation through the left ventricle using a peristaltic pump at a low flow rate in order to 
flush blood from the circulatory system.  Blood and PBS coursed through the circulatory 
system, and exited through the cut inferior vena cava on the way back to the heart, 
draining into a collecting basin beneath the mouse. 
7. When fluid draining from the IVC turned clear, a switch was made to cold Zamboni’s 
fixative (2% paraformaldehyde, 15% picric acid in PBS, pH 7.4).  Perfusion with 
Zamboni’s fixative continued until the feet, tail, and tissues around the nose and mouth 
picked up a yellow tint from the Zamboni’s fixative, and the limbs/tail stiffened. 
Perfusion at this point was discontinued. 
8. Using a small pair of scissors, an incision was made at the bridge of the nose between the 
eyes of the mouse. 
9. Using a small pair of forceps, the front part of the skull was alternately peeled away or 
broken starting at the incision between the orbits.  The bottom prong of the forceps was 
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gently worked into the space between the brain and skull as the skull was carefully 
removed to expose the brain.  Care was taken not to damage the brain tissue. 
10.  The occipital lobe was removed last, with great caution taken to avoid damaging the 
cerebellum or brainstem. 
11. The head of the mouse was flexed forward to allow insertion of the bottom prong of the 
forceps into the spinal canal starting with the first cervical vertebra.  The forceps were 
used to expose the brainstem and spinal cord, vertebra by vertebra, down to the level of 
the 2nd to 3rd thoracic vertebra. 
12. The meninges covering the brain and spinal cord were identified, then gently peeled 
away. 
13. Using the forceps, remaining bits of skull and vertebrae were removed from around the 
brain and spinal column.  The forceps were used to feel for sharp edges of bone prior to 
removal of the brain. 
14. Using a dull scalpel, the brain was gently separated from the base of the skull by inserting 
the scalpel underneath the brain, gently severing cranial nerves and vessels, slowly lifting 
the brain, working from the olfactory bulbs back to the brain stem. 
15. Once the brain and spinal cord were separated to approximately the 2nd or 3rd thoracic 
vertebrae, the spinal cord was cut as low as possible and the brain removed. 
16. The freshly excised brain was placed into cold Zamboni’s fixative and allowed to postfix 
overnight. 
17. After postfixing, the brain was transferred into a 30% sucrose solution for cryoprotection.  
Initially, the brain would float near the surface of the sucrose solution.  
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18. After the brain had sunk to near the bottom of the sucrose solution, it was removed and a 
razor was used to cut away the cerebellum and brainstem. The cerebellum was then 
separated from the brainstem and discarded.  
19. The brainstem and cortical/midbrain tissues were then embedded in Tissue-Tek O.C.T. 
Compound (Sakura Finetek, USA) and frozen at -80o C. 
Nissl Staining 
Trial 1 
 Three month-old FVB and OVE26 mice brains were used in this study, and the tissues 
were transferred to a cryostat (HM 505N) and mounted on a plate using freezing medium at a 
setting of -25°C. 12 μm coronal sections of the hippocampus and olfactory bulb were cut. Mice 
classified with the letter “L” were normal, while mice classified with the letter “D” were 
diabetic.  
Table 1: Sections from Normal and Diabetic Mice 
Mouse  
Identification  
Hippocampus 
Slices 
Olfactory 
Slices 
Notes 
L18 Yes Yes  
L121 Yes Yes  
D101 Yes Yes  
D107 Yes Yes  
D110 Yes No Olfactory bulb was very dry and kept crumbling; 
unsalvageable 
 
 Nissl staining using cresyl violet was used to visualize the morphology of the neurons 
and perform cell counts on sections capturing the hippocampus and olfactory bulb. The staining 
was performed as follows. Slides containing the sections were permitted to air dry for 15 - 30 
minutes prior to immersion into a series of twelve solutions for staining: 95% ETOH for 15 
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minutes, 70% ETOH for 1 minute, 50% ETOH for 1 minute, DH2O for 2 minutes, DH2O for 1 
minute, Cresyl Violet stain for 15 minutes, DH2O for 1 minute, 50% ETOH for 1 minute, 50% 
ETOH for 1 minute, 70% acid ETOH for 2 minutes, 95% ETOH for 2 minutes, 95% ETOH for a 
few dips, and finally 100% ETOH for 1 minute.12 
Trial 2 
 
The protocol in trial 1 presented many challenges to data collection, in that the brain 
tissues had inherent damage, and the procedure for dehydrating the tissues proved too extreme 
and contributed to small perforations seen under the microscope, especially since the sections 
were only 12 μm thick. Therefore the protocol was modified and optimized, and applied to newly 
cut 30 μm slices. Instead of dipping the slides into a series of solutions, a pipette was used to 
deliver the solutions to each slide gently, so that minimal disruption would occur to the tissues. 
Each slide was treated with cresyl violet for eight minutes, and then rinsed with 1x PBS buffer 
two to three times. Then each slide underwent three rounds of treatment with Histoclear for three 
minutes each, rinsing with 50% EtOH twice in between. Finally the slide was rinsed in 1x PBS 
buffer and allowed to air dry prior to being fitted with a coverslip using mounting media. The 
slides were viewed at 200X magnification, and individual photos of each field of view were 
taken and compiled into mosaics via the software ImageJ.13 The DG, CA1, CA2, and CA3 
regions of the hippocampus were identified, and the neurons in five different 200 μm2 areas were 
counted using Inkscape and averaged. 
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Figure 1: Counting technique using 200 micrometer grids via Inkscape 
Fluoro-Jade C 
 Fluoro-Jade C is a form of fluorescent histological staining used to highlight neurons in 
the process of degeneration.14 Slides containing 12 μm thick hippocampal slices of OVE26 and 
FVB mice were utilized. 1% NaOH in 80% ethanol was pipetted onto each slide for five minutes, 
followed by 2 minutes of 70% alcohol, and then 2 minutes of diH2O. Then 0.06% potassium 
permanganate was placed on the slides for 10 minutes, before the slides were rinsed with 
distilled water for 2 minutes. 0.0001% Fluoro-Jade C in 0.1% acetic acid was then added to the 
slide for 10 minutes, and the slide was incubated in the dark during this interval. Six consecutive 
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1 minute washes in distilled water followed, and then the slides were allowed to air dry for 5 
minutes. Lastly, the slides were cleaned with Histoclear for 5 minutes, allowed to dry, and then 
cover-slipped for visualization at 488 nm on the confocal microscope. 
Immunohistochemistry: Musashi-1 
 Musashi-1 is a mouse RNA-binding protein that is highly expressed in the stem cells of 
the central nervous system.15 Because it is expressed highly in neuronal and glial precursor cells, 
and then its presence virtually disappears once the cell has fully differentiated, it is a prime 
marker for detecting neurogenesis in tissue samples.15 For the preparation of each solution, refer 
to Appendix B.  
 First, sections of the hippocampus were selected and hydrated by pipetting 50% EtOH 
onto the slides for 30 seconds. Then the tissues underwent six 1.5-minute washes in PBS buffer 
while being agitated on a rotating shaker. The excess moisture was removed from the slides, and 
then a Super Pap Pen was used to draw circles around each individual section so that when the 
antibodies were added they would concentrate on the sections themselves, and not migrate to 
unoccupied areas on the slide. 15 mL of blocking solution containing BSA and normal donkey 
sera was added to the slides, and they were incubated on a rotating shaker at room temperature 
for two hours. Then 1.5 mL of primary antibody (1 μg/mL) were incubated overnight for 
approximately 16-18 hours at 4°C in a humidified chamber. This was followed by 6 five-minute 
washes in PBS-T while on the rotating shaker at room temperature. The secondary antibody 
(1:500) was then incubated for two hours at room temperature, and the slides were again rinsed 
with 6 five-minute washes with PBS-T on the rotating shaker. The slides were viewed on a 
confocal microscope at 543 nm for excitation and 625 nm for emission. 
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RESULTS 
 
Figure 2: A) OVE26 Mouse Hippocampal Mosaic Slide 18A and B) DG at 40X 
 
CA1 
CA2 
CA3 
DG 
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Figure 3: A) FVB Mouse Hippocampal Mosaic Slide 30 at 20X B) DG at 40X 
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Figure 4: Diabetic DG depicting hyperchromatic neurons 
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Figure 5: Normal DG depicting hyperchromatic neurons 
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Figure 6: Number of Hippocampal Neurons in the Diabetic versus Normal Mouse 
 
 Images were taken with a light microscope at 200X magnification of OVE26 and FVB 
brain sections, then merged in MosaicJ by overlapping landmarks in the photos (Figures 2 and 
3). Neurons were counted in the DG, CA1, CA2, and CA3 regions using 200 μm fields of view 
generated through Inkscape. Then an average was taken and the results were graphed, revealing 
that in all four areas, diabetic mice led with the highest number of hyperchromatic neurons, and 
the differences were statistically significant in the dentate gyrus and CA1 region (Figure 6). Then 
a view of the dentate gyrus in each was procured at 400X, in order to determine whether there 
were differences in the degree of staining, in other words whether diabetic neurons absorb more 
cresyl violet than their normal counterparts (Figure 2B and 3B). The comparison revealed that 
diabetic neurons were hyperchromatic and stained more darkly. The arrows in Figure 2 and 
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Figure 4 depict hyperchromatic neurons in the diabetic brain, which were consistently more 
highly stained in comparison to the background tissue than the neurons depicted in Figures 3 and 
5 for the normal mouse. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Fluoro-Jade C Staining of diabetic dentate gyrus at 40X as a Mosaic 
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Figure 8: Fluoro-Jade C stain of normal dentate gyrus at A) 40X as a mosaic and B) 1000X 
A 
B 
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Figure 9: Fluoro-Jade C diabetic DG at higher magnification 
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Figure 10: Fluoro-Jade C normal DG at higher magnification 
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Figure 11: Trial 2 for Fluoro-Jade C diabetic DG as a 40x mosaic 
 
 
Figure 12: Fluoro-Jade diabetic stained cell at 100X from box in Figure 11 
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   Figure 13: Trial 2 for Fluoro-Jade C normal DG as a 40x mosaic 
 
Figure 14: Number of degenerating neurons in DG using Fluoro-Jade 
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The Fluoro-Jade C stains were viewed under a confocal microscope at 488 nm at 40X 
magnification, with a focus on the dentate gyrus. Mosaics were made for both the diabetic and 
normal mice, both depicting the presence of degenerate neurons via the presence of hotspots 
consisting of fluorescent green pigment (Figures 7 and 8A). Examples of degenerate neurons in 
both tissue types are labeled with orange arrows in Figures 9, 10, 11, and 13. When counts of the 
mosaics were performed, the number of degenerate neurons in the diabetic dentate gyrus 
exceeded that of the wild type (Figure 14). In addition to degenerating neurons, which are 
normally more oblong and irregularly shaped, some of the glial cells in the tissue also appear to 
be degenerating, and are characterized as very round green intensities (Figure 8B and 12). 
The first trial of Fluoro-Jade staining produced a greenish border around the dentate 
gyrus of the diabetic sections, and a more faint border around the normal dentate gyrus, labeled 
with yellow arrows in Figures 9 and 10. At first, it was thought to be background staining due to 
insufficient rinsing or too little tissue clearance with Histoclear. However a second trial in which 
the number of rinses was doubled, and the time exposed to Hisoclear increased from 3 minutes to 
five minutes showed less background staining, but the same green border around the dentate 
gyrus (Figures 11 and 13). The diabetic sections consistently showed more pigment in this area 
than the normal hippocampal sections, leading to the possibility that there is increased 
neurodegeneration in the ependymal cells as well as the DG neurons of the diabetic mouse in 
comparison to the normal. 
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Figure 15: Mushashi-1 immunohistochemistry for wild type DG slide 37 at 20X 
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Figure 16: Musashi-1 immunohistochemistry of diabetic DG at A) 20X and B) 40X 
A 
B 
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 Immunohistochemistry using Musashi-1 antibodies was used to detect for differences in 
neurogenesis. Figure 15A shows a part of the dentate gyrus for the wild type mouse at 20X, 15B 
is at 40X magnification, and C1-C3 are consecutive 0.5 um slices through the section in panel B. 
Figure 16A is an image of the diabetic dentate gyrus with a close-up of one panel at 40X. Ideally 
there should have been a higher number of fluorescent hot spots for the wild type mouse, 
indicating decreased neurogenesis in the diabetic model. However, in both tissues there was a 
high degree of non-specific binding making these results inconclusive. Even the pattern of 
fluorescence that was present did not suggest that the antibody bound specifically, since 
Musashi-1 should be found cytoplasmically, but the antibody instead outlined the neurons from 
this trial. This is depicted by the green arrows in Figures 15 and 16, where the borders of neurons 
are clearly seen but very few antibodies penetrate the interior in comparison to the rest of the 
tissue. There may be a pattern in the binding, but it is difficult to interpret without a secondary 
stain. 
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DISCUSSION 
Analysis of Results 
 Nissl staining is performed with basic dyes, such as the cresyl violet used in these 
experiments, and binds to the negatively charged nucleic acids present in the nucleus of the cells, 
as well as the endoplasmic reticulum.12, 16 Because the cells in brain tissue all contain these 
components, the stain does not differentiate between glia and neurons, but the neurons retain 
more of the stain because of their high rate of protein synthesis, and are also distinguishable by 
the irregular shape of their dendritic spines.16 When these neurons sustain any type of damage 
and begin to undergo degeneration, the stain increases in density and the cells are considered to 
be “hyperchromatic.”17 The results of the Nissl stains performed in these experiments indicate a 
greater number of hyperchromatic cells in the DG, CA1, CA2, and CA3 regions of the 
hippocampus for diabetic mice in comparison to the wild type control. By extension this means 
that the hippocampus of a diabetic mouse sustains greater levels of neurodegeneration than the 
normal, and the expected clinical manifestation would be cognitive deficit based on evidence 
from the literature. 
To confirm that the hyperchromatic neurons observed were in fact degenerating, and not 
merely histological artifacts, a second set of experiments was conducted using Fluoro-Jade C. 
The precise mechanism of this stain is unknown, however, the present theory is that dying 
neurons release strongly basic molecules that attract the acidic Fluoro-Jade to it.18 This basic 
“degeneration molecule” is a byproduct of the process of neurodegeneration and is inaccessible 
to Fluoro-Jade unless the cell membrane is disrupted, therefore making it a prime indicator for 
neuronal cell death.18 The data collected using confocal microscopy and this staining technique 
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clearly demonstrated an increased level of neurodegeneration in the diabetic mouse model in 
comparison to the wild type control. Moreover, there was also a larger number of fluorescent 
glial and ependymal cells present in the diabetic brain sections, revealing that diabetes decreases 
the presence of these cells in the dentate gyrus as well. 
 Musashi-1 was used to quantify the number of progenitor stem cells in the hippocampus 
of the diabetic and normal mice, in order to determine whether diabetes disrupts neurogenesis in 
the dentate gyrus. The target of the antibody, Musashi-1, is a protein that binds RNA and is 
expressed predominantly in the progenitor cells, and undergoes down regulation once the cell has 
fully differentiated.19 With regards to the Musashi-1 experiment, the results obtained were 
inconclusive. Despite the fact that binding of the antibody did occur in both tissues, most of it 
appeared to be non-specific, especially since the protein being sought out is cytosolic, whereas 
the data obtained showed a great deal of membranous binding, as depicted by the way the 
antibodies often outlined the neurons in the tissue as opposed to penetrating them. This is most 
likely due to secondary antibody becoming trapped between the cells, rather than a true 
antibody-antigen interaction.   
 In the future, we would like to perform a greater number of trials with Fluoro-Jade C to 
add more weight to the conclusion we obtained, which is that diabetes does incur greater 
neurodegeneration in the hippocampus. Moreover, the Musashi-1 immunohistochemistry 
protocol needs to be optimized in order to reduce non-specific binding and increase the 
penetration of the antibodies into the brain tissue. This could be accomplished by using 8 μm 
slices instead of 12 μm sections, and by blocking the tissue with BSA overnight as opposed to 
only blocking for two hours. The concentration of BSA was also determined to be only 2%, 
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when typically a 10% blocking solution is utilized, so a change in this regard would greatly 
reduce nonspecific binding. Another possible change to the protocol to make interpretation of the 
data more efficient would be incorporating a double stain with β-tubulin III, which would 
produce an inline of the neurons and would help us determine where these Musashi-1 antibodies 
are binding.  
Moreover, we would like to attempt this immunohistochemical procedure with sections 
of the olfactory bulb, to determine whether neurogenesis is inhibited in this area in diabetic mice. 
This would be of significant importance because there are many neurodegenerative diseases that 
have been linked to reductions in the sense of smell.20 The remainder of this thesis is dedicated to 
exploring the clinical manifestations of increased neurodegeneration and decreased neurogenesis 
in the hippocampus, the potential mechanisms behind neuronal cell death and cognitive decline, 
and how these findings may influence current and future treatments of diabetes mellitus. 
Cognitive Impairment  
Clinical Manifestations 
 As treatments for insulin resistance improve and as patients continue to live longer with 
diabetes mellitus, the effects of this disease have shown to be clinically more widespread than 
previously thought, with effects reaching as far as the skeletal system and the CNS.21 In type 2 
diabetics especially, direct correlations were made between elevated A1c levels and poor 
performance on tests evaluating neurocognition, showing an inverse relationship between 
glycemic control and cognitive performance.21 With regards to type I diabetics, moderate 
 29 
declines in processes related to problem solving, mental and motor speed, learning, and memory 
were noted as well.7 
 Multiple studies have been performed evaluating the cognitive performance of diabetics 
by relating the scores they receive on various tests to their blood sugar levels. When comparing 
type I diabetics with an HbA1C level of less than 7.4% to those with a level greater than 8.8%, 
the general trend shown was that the greater the glycemic control, the better the person’s 
performance in academic achievement, verbal IQ scores, psychomotor efficiency, and memory.8 
A hyperglycemic state was also associated with loss of focus, decreased speed in information 
processing, and a larger number of errors in mental subtraction.8 
 Hypoglycemia too has been thought to be involved in the clinical manifestations of 
neurocognitive decline, especially with regards to recurrent hypoglycemia or severe 
hypoglycemic episodes requiring third party assistance. When a diabetic patient was presently 
hypoglycemic, their performance in terms of prospective, delayed, immediate visual, and 
working memory was impaired, along with their visual-motor skills and visual-spatial skills.8 
This occurred regardless of whether the patient was aware or unaware of their low blood sugar.8 
It is the effects of recurrent hypoglycemia that interest researchers the most however, because its 
long-term impact on patients' cognition in a euglycemic state is what produces mixed results.8 
Currently, such persons have been observed to have lower IQ scores, verbal skills, memory, and 
attention, although even those who had a history of severe episodes did not show greater 
impairment than diabetics who did not have that history upon performance of an eighteen-year 
follow-up.8 The risks of having a hypoglycemic blood sugar level are often increased the greater 
the glycemic control, especially if the patient is undergoing intensive insulin management in 
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order to minimize their risks for vascular disease.8 It would therefore be of significant concern if 
hypoglycemia was a culprit of severe cognitive decline, and providers and patients had to 
balance the benefits of maintaining blood sugar with the risks of cognitive dysfunction. However 
the current evidence is not really supportive of this view, as a study done on children who had 
frequent hypoglycemic episodes showed that they had higher verbal and memory scores, not to 
mention academic achievement, than diabetic children with less glycemic control.8 This would 
allow researchers to hazard the opinion that overall, the benefits of more stringent glycemic 
control compensate for any neurocognitive damage instigated by hypoglycemia.8 
 Despite the decrease in cognitive capacities in hypo- and hyperglycemic states, patients 
suffering from diabetes mellitus are still at a cognitive disadvantage even in euglycemia. If 
compared to their respective controls, type I diabetics consistently score less in overall cognition, 
speed of information processing, visual and sustained attention, visual perception, mental 
flexibility, and crystallized intelligence.8 On average, those with type 2 DM exhibit decreased 
working memory, immediate and delayed recall, verbal fluency, executive function (also 
considered to be frontal lobe function), processing speed, attention, and verbal retention and 
fluency.8 Whether as a result of hypoinsulinemia or a reduction in the body’s ability to respond 
to insulin, the distributional pattern of glucose metabolism in diabetic patients as they work on 
memory tests is altered, showing more widespread activity in brain regions adjacent to those 
normally activated during such tasks.22 Although it has yet to be confirmed whether these 
observations are the result of cerebral defects, diabetic patients also present with a lack of 
balance, slower walking, and a greater potential for falling.8 
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 As patients with diabetes progress to having complications such as angiopathy, changes 
in functionality manifest by way of decreases in the connectivity and synchronization of neural 
networks between different parts of the brain.22 Functional MRI revealed that type I diabetic 
patients with microangiopathy suffered a reduction in functional connectivity in five separate 
neural networks.22 These include the secondary visual network, ventral attention network, 
sensorimotor network, language-processing network, and the left frontoparietal network.22 
However, researchers were startled to find that while type I diabetics without microangiopathy 
suffered from a decrease in functional synchronization in three of these networks, they actually 
had greater connectivity in the sensorimotor and secondary visual networks than even 
nondiabetics.22 Moreover, this has also been observed in patients with other pathological states 
of the brain such as cognitive impairment and multiple sclerosis.22 Because the acquisition of 
microangiopathy is considered to be characteristic of a later stage of diabetes, researchers have 
come to the conclusion that as diabetes begins to incur minor brain damage, the brain undergoes 
“functional reorganization” in a compensatory effort to stem the tide of dysfunction, thereby 
increasing the functionality of certain areas.22 However, as seen in other diseases such as 
multiple sclerosis, synchronization in brain activity eventually declines in all five networks.22 
Also from a functional perspective, the electrophysiological changes in diabetic patients 
also correlate to the progression of the disease as response potentials to certain stimuli actually 
reveal a decrease in nerve conduction velocity.8, 23 The P100 wave for example is a potential that 
is visually evoked and thought to originate in the visual cortex.7 The longer the patient has had 
diabetes and the higher their HbA1C level, the greater the latency of that potential.7 Flash 
electroretinopathy confirms this based on the fact that even before any opthalmoscopic 
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indications of retinopathy are present, there are reduced potentials sent out from the retina.8 The 
nerve response to acoustic stimuli is abnormal as well, and the auditory-evoked potentials from 
the brainstem in diabetic patients are characteristic of “acoustic pathway impairment.”8 
Moreover, the event-related P300 wave associated with memory processes and used particularly 
whenever a target stimulus must be identified from the midst of standard stimuli has been shown 
to have greater latency, and could be related to defects in attention and short-term memory in 
type 2 diabetics.7, 8 Though normally seen in typical aging, the decrease in conduction velocity of 
the P300 wave is much more pronounced in diabetics, and central somatosensory-evoked 
potentials are also delayed.7, 8 To assess electrical activity in the cerebrum, EEGs were also 
performed on diabetics, and in patients with type 2 DM there was “slowing in the EEG 
frequency band analysis over the central cortex and reduction of alpha activity over the parietal 
area.”8 When compared to outcomes of neurocognitive tests, these results were correlated to 
reduced visual retention and could only be accounted for by the presence of diabetes because 
hyperglycemic nondiabetics did not express these findings.8 Furthermore, because diabetes often 
manifests as accelerated aging, decreases in hippocampal synaptic plasticity have been observed 
and implicated as being one of the major causes of the disadvantages that affect diabetics in 
terms of both memory and learning.7 According to Saladin, synaptic plasticity describes the 
ability of the brain to transmit potentials from one neuron to another to create new connections, 
and the ease with which this transmission occurs down a familiar neural circuit is related to how 
memories are retained and new tasks are learned, or synaptic potentiation.23 Afferent activity at a 
high frequency induces what is called long-term potentiation, while long-term depression occurs 
when there is a prolonged period in which a low-frequency stimulus is detected, thereby causing 
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a reduction in the strength of the synapse.7 Aging, or accelerated aging in the case of diabetes, 
results in an increase in the threshold needed to induce an LTP and a decreased threshold for an 
LTD.7 
 One of the many concerns that has arisen for patients with diabetes is the increased 
prevalence of both Alzheimer’s and vascular dementia in this subset of the population, even 
when other cofactors and comorbidities are taken into account.21 In diabetics, the risk of 
acquiring dementia is actually doubled in comparison to non-diabetics, and a theory currently 
exists insinuating that Alzheimer’s and insulin resistance may have the same or at least a similar 
pathogenesis.7 Secondary to these debilitating cognitive states in the later years, elderly diabetics 
were also found to be twice as likely to suffer from depression, which also affects their ability to 
perform daily abilities and function cognitively.8 Epidemiological studies have shown that 11.3% 
were cognitively impaired, 14.2% had clinical depression, and 17.5% had “moderate to severe 
deficits in activities of daily living.”8  
 So far the signs and symptoms of decline noted were observed in older diabetics from 
mid-life on, which might suggest that age is a necessary component for seeing the detrimental 
effects of DM on the brain. However these cognitive deficits can be seen as early as childhood 
and become more obvious the earlier the onset of the disease. From the age of two, children 
diagnosed with DM show less positive incremental changes in learning with regards to block 
design, speed of processing, general intelligence and vocabulary.8 By the time six years have 
transpired since the time of diagnosis, they begin to manifest with debilitations in long-term 
memory, executive function, processing speed, attention, and IQ.8 In those diagnosed at less than 
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four years of age, the impairment in processing speed, executive skills, and attention was 
significantly greater than in those who acquired diabetes after the age of four.8 
 Gender also elicits a difference in cognitive effects, as a greater performance gap exists 
between diabetic men and their controls in tests of strength grip, oscillation, and somatosensory 
ability in comparison to the deficit observed between female diabetics and their respective 
controls.8 In addition, worse glycemic control correlates to a verbal intelligence decline in boys 
ages seven through sixteen, an effect that is absent in their female counterparts.8 
Modifications in Macrostructure 
 Upon examination, the brains of diabetic patients have revealed that these clinical 
manifestations of cognitive decline are linked to changes in the macrostructure of the brain, and 
more specifically, atrophy. Moreover, the extent of the atrophy is linked to the age at which 
onset of the disease occurred, the prevalence of hypoglycemic episodes in the patient’s life, as 
well as whether he or she was known to suffer from chronic hyperglycemia.21 Because these 
factors vary from patient to patient, it explains precisely why the epidemiological studies done 
on diabetics have mixed results regarding the localization and extent of these structural changes 
on the brain.7, 22 
 Young adults diagnosed with type I diabetes in childhood, for example, exhibit reduced 
white matter volume and changes in its microstructure, as well as reduced gray matter density 
associated with memory and language processing.21 Children with severe hypoglycemic episodes 
too show decreases in posterior parietal white matter, and in the gray matter of the cuneus and 
precuneus gyri.8 Voxel-based morphometric studies indicate that the location of GM density loss 
varies based on diabetic conditions, as those suffering from chronic hyperglycemia show reduced 
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density in areas responsible for attention, memory, and language, while those with a history of 
multiple hypoglycemic episodes have less GM in the cerebellar posterior lobe.8  The reduction in 
density in type I diabetics was found predominantly in the thalamus, temporal lobe, and frontal 
lobe. Strangely, diabetic children with a history of severe hypoglycemia exhibit a higher GM 
density in the right prefrontal cortex, an area thought to correlate to self-recognition.8, 24  
 Studies have also discovered localized atrophy in the amygdala and hippocampus, 
regions that also show degeneracy in Alzheimer’s disease.8 In other cases, certain areas of the 
brain in type I diabetics were associated with disorganization of typical white matter tracts that 
showed more preservation the greater the long-term blood sugar control.22 White matter tract 
aberrations were also associated with areas of greater myelin degeneration, and may be linked to 
the declines in cognitive performance.22 
If diabetes mellitus leads to the complication angiopathy, diffuse abnormalities can occur 
in the brain in patients younger than the age of forty, characterized by degenerative 
modifications that are so marked that a dual pathogenesis has been implicated.7 Researchers have 
concluded that the cerebral atrophy characterized by “widened sulci and/or enlarged ventricles” 
on MRI and CT must be due to the combined effects of diabetic abnormalities in neural tissue 
and ischemia induced by the angiopathy.7 Magnetic resonance imaging has also revealed the 
presence of white hyperintensities that may be linked to the autopsy finding of ischemic lesions.7 
Strongly correlated to the aging process, leukariosis in the white matter and basal ganglia have 
been a consistent presence in the brain tissue of both type I and type 2 diabetics.8, 25  
From a volumetric standpoint, significant changes have been observed in diabetic patients 
that would indicate quite clearly that the aging process is not only accelerated on a cognitive, but 
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anatomical level as well. Magnetic resonance imaging revealed that diabetic patients have on 
average 2.5 cm3 of abnormal tissue, consisting of 5% grey, 8% deep gray, and 81% white 
matter.25 The longer the duration of DM and the higher the fasting plasma glucose level, the 
lower the normal tissue volume and the larger the ischemic lesions.25 The lesions themselves are 
believed to be the result of “nonnecrotic demylination” originating from insufficient blood flow, 
and have been linked to balance, gait, and cognition.25 In the long-term, a difference of 10 years 
in diabetic onset made a difference of 4.28 cm3 in total gray matter and could not be accounted 
for by the normal aging process, which typically only results in a loss of 2.4 mL.25, 26 As a result, 
the brain of a diabetic patient looks roughly two years older than that of a nondiabetic for every 
ten years of disease duration.25  
One of the more unexplained phenomena with regards to macrostructural changes in the 
brain involves the effect of recurrent hypoglycemic episodes in children with diabetes.21 
Contrary to the data collected on adults with type I diabetes, in whom hippocampal volumes 
remained consistent despite chronic hypoglycemia, children who had an early onset of DM and 
also had chronic hypoglycemia had increased hippocampal volumes.21 The theory at present is 
that the brain in a state of development will respond to hypoglycemic conditions in a different 
manner than an adult brain.21 
Potential Mechanisms of Pathophysiology 
 The pathophysiology of diabetes mellitus continues to remain elusive, making it difficult 
to target the causative agents of cognitive dysfunction and therefore deliver a treatment.8 
However multiple theories have been proposed, and it is possible that a combination of these is 
responsible for the accelerated brain aging found in diabetics. 
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 Because diabetes affects the cardiovascular system by changing the nature of blood 
vessels and their ability to perfuse certain tissues, these modifications have been implicated in 
the cerebrovascular changes responsible for cognitive deficits. In addition to intracranial vessel 
atherosclerosis, which is partly responsible for the two to six-fold increase in the likelihood of 
thrombolytic stroke in diabetic patients, other microvascular abnormalities exist such as 
thickening of the basement membrane in capillaries.7, 8 The microvessels undergo endothelial 
degeneration, the walls of larger vessels accumulate more collagen and become inflexible, and 
there is an overall decrease in perivascular nerve density.7 Hyaline atherosclerosis occurs in the 
smaller vessels (with diameters less than one nanometer), and involves replacement of the 
smooth muscle with fibrous tissue that thickens the intima.7  
Changes in the blood flow of the brain consequently contribute to cerebral insult. For 
example cerebral blood flow levels in type 2 diabetics at rest and in response to hypercapnia are 
both markedly lower than those in their respective controls, and it has been theorized that prior to 
detectable structural changes in the brain, the pathology begins at the level of hemodynamics as 
the cerebral microcirculation begins to undergo modification.22 Any type of aging, whether it be 
normal or the accelerated form seen in diabetes, results in a decrease in the ability of the cerebral 
blood vessels to autoregulate their response to perfusion pressure changes.7 Vasomotor tone 
regulation is diminished, and could be linked to the decreased density of VIP and serotonin-
containing nerves found in STZ-injected rats.7, 22 Decreases in vasodilation mediated by nitric 
oxide and increased vasoconstriction in the arterioles, along with hypertrophy of the smooth 
muscle found in precapillary vessels have also been observed.7, 22 Patients with diabetes also 
seem to have reduced levels of C-peptide, which when normalized increased cognitive function 
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in humans and decreased hippocampal apoptosis in the rat model.8 This is due to C-peptide’s 
actions in the endothelium, which involve its binding to a G-protein coupled receptor and 
beginning a cascade of events that not only trigger the expression of nitric oxide synthase 
(involved in vasodilation), but activate several transcription factors involved in mechanisms that 
are anti-oxidative and anti-inflammatory.8, 27 Diabetic patients also seem to have greater 
stimulation of the thromboxane A2 receptor, which may be responsible for the decreased 
capacity of cerebral vessels to dilate as well.8   
As regions of the brain receive less blood, cell death occurs and the cell loss results in an 
additional decline in cerebral blood volume because the metabolic demands of the brain have 
been consequently altered.7 This phenomenon is observed in normal aging at a less drastic rate 
than in diabetic patients, and is also accompanied by morphological changes in neurons and glia 
as the state of chronic hypoperfusion continues.7 In rats, the hippocampal CA1 neurons, which 
are especially susceptible to the effects of ischemia, display higher levels of astrocyte 
components and a reduction in microtubule-associated protein 2 in the dendrites.7 Lower 
microtubule-associated protein 2 is actually an indication of early ischemic damage, and because 
astrocytes are responsible for replacing dead tissue via the process of sclerosis or scarring, an 
increase in astrocyte levels is also an indicator of cerebral ischemia.7, 23 As a result of vascular 
disease that has developed due to the progression of DM, these patients often exhibit structural 
changes such as demyelination of the spinal cord and cranial nerves, pseudocalcinosis, nerve 
fibrosis, and brain degeneration throughout.8 
Many theories exist to explain how hyperglycemia may be causing the detrimental 
structural and cognitive changes in both type I and type 2 diabetics. The first is that 
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hyperglycemia increases the flux going through the polyol pathway, a biosynthetic progression 
involving two enzymes that convert glucose into sorbitol and fructose.8, 28 Sorbitol has been 
correlated to an increase in diabetic lesions in the CNS, so if more substrate is present there will 
be greater conversion to sorbitol.28 This substance has also been located in the peripheral nerves 
of STZ-treated rats.8 Upon treatment with an aldose reductase inhibitor, the levels of sorbitol 
decreased drastically and normal cognitive function was restored.8 Another possibility is that 
excess glucose is shunted to the hexoamine pathway for the production of cerebral chitin, a 
molecule that accumulates in Alzheimer’s patients and may also be the cause of abnormal 
cognition in diabetics.8 
Hyperglycemia can also result in accelerated AGEing, which refers to advanced glycated 
end-products that are a form of non-enzymatic protein glycation caused by the high 
concentration of glucose in the blood.7 This is an irreversible reaction that occurs as a function of 
time and the concentration of reduced sugars resulting in a linkage with the free amino groups of 
proteins.7 AGEs are found in normal aging, but concentrations are considerably higher in those 
with DM or Alzheimer’s, and their production has been linked to an increase in ROS in cells.7, 8 
AGEing also causes modification of the endothelial basement membrane, contributing to 
vascular dysfunction and the decreased ability of blood vessels to respond to nitric oxide for 
vasodilation.7 Thus AGEing may contribute to ischemia in the brain, which in turn could lead to 
neuronal cell death. These substances have also been linked to higher levels of oxidative stress in 
the diabetic brain, as observed by increased levels of lipid peroxidation products.7, 8 The number 
of oxidized, dysfunctional proteins in the neurons is increased because there are higher levels of 
reactive oxygen species being produced as the result of glucose autoxidation.7 Moreover, 
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enzymes like SOD and glutathione catalase which function as ROS scavengers are also 
irreversibly glycated and consequently have reduced functionality as the body’s natural 
antioxidants.5 Certain markers linked to these biochemical changes have been found to be up-
regulated in the hippocampus, such as nuclear factor κB transcription factors and the S-100 
protein.8 The former is a proinflammatory gene marker that is activated in the presence of AGEs, 
while the latter is indicative of brain injury and binds to receptors for AGEs.8   
In concert, hyperglycemia and ischemia have proven to be a dangerous combination, and 
the elevation of blood glucose has been correlated to less efficient clinical recovery from 
cerebrovascular events.8 The underlying mechanism is thought to be glutamate accumulation, 
which occurs during hyperglycemia as the excitatory neurotransmitter causes damage to the 
neurons when ischemic conditions are present.8 Another theory is that hyperglycemia 
exacerbates ischemic damage by providing more substrate for conversion into lactate; this lactate 
then results in cellular acidosis which potentiates the brain injury.8 
On the other side of the spectrum, hypoglycemia too has been implicated as a pathogenic 
mechanism for the neurological damage seen in diabetes. Normally seen as a result of tight 
glycemic control, the areas most sensitive to hypoglycemic damage are the hippocampus, basal 
ganglia, and cortex according to autopsy reports.8 The effects seem to be isolated to neurons 
exclusively, while sparing oligodendrocytes and astrocytes, and present as multifocal or 
widespread necrosis of the cerebrum.8 The ganglion cells also exhibit chromatolysis.8 Although 
once thought to be a passive process in which neurons simply died of starvation, in reality 
hypoglycemia may actually induce a cascade of events that result in overactivation of the 
excitatory NMDA receptor.8, 29 This overactivation is by the massive release of aspartate, which 
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targets the dendrites causing calcium fluxes that in turn cause membrane dissolution and 
necrosis.29, 30 This would therefore make cell death the result of endogenous excitotoxins, which 
in turn would explain the seizures present in severe clinical cases of hypoglycemia.30 Unlike 
ischemia, which normally affects the brainstem and cerebellum, these regions are spared in 
hypoglycemia and instead necrosis is typically detected in the dentate gyrus of the 
hippocampus.29 There is therefore therapeutic potential in an NMDA receptor antagonist that 
would shield type I diabetic children from possible hypoglycemic damage.8 
Because intracellular concentrations of Ca2+, as well as the signal transduction cascades 
induced by them, play a role in the pathway leading to neuronal cell death in the normal aging 
process, an imbalance in Ca2+ is a possible mechanism for the cellular changes observed in the 
CNS of diabetic patients.7 According to the literature, a drastic change in the calcium 
concentration over a short duration produces the same amount of damage as an incremental 
damage over a long period of time, and disruptions in calcium homeostasis are linked tightly to 
ischemia, cell death, and the production of reactive oxygen species.7 Although there are few 
details on precisely how this imbalance occurs, it does seem to influence the changes in LTD and 
LTP observed in diabetic patients.7 
Moreover these changes in cognition may be accounted for by decreases in hippocampal 
synaptic plasticity, as well as fluctuations in neurotransmitter levels or their respective receptors. 
According to studies done on STZ-injected rats, the deficit in plasticity is mainly postsynaptic 
and the induction of diabetes in these rats was quickly followed by increased sensitivity to 
adenosine, an inhibitory neuromodulator.7 Believed to be caused by reduced nucleoside uptake, 
it is thought that increased levels of adenosine play a role in long-term potentiation deficits, since 
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LTP is modulated by adenosine.7 Synaptic transmission is dependent upon effective binding of 
glutamate to NMDA and AMPA receptors, so it is interesting to note that in diabetic rodent 
models, the density of NMDA receptors found in the hippocampus is significantly reduced.7, 8 
Moreover, glutamate has a decreased affinity for AMPA receptors because the GluR1 subunit 
has reduced expression.7 The result is an impairment of LTP, which is a cause of learning 
deficits and can be ameliorated by insulin treatment.8 Other observations include decreases in 
ACh levels, which led to amnesia and hyperactivity in STZ rats in relation to the control, 
decreased dopamine activity, and lower serotonin degradation.8 The conclusion arrived at by 
researchers is that fluctuating blood sugar levels seen in patients with poor glycemic control have 
a detrimental effect on the function of multiple neurotransmitters in the brain.8 
Perhaps the biggest lead with regards to why diabetes mellitus increases and exacerbates 
cognitive decline in patients comes from the very cause of diabetes mellitus itself: insulin 
resistance. Although the effects of insulin on metabolism in peripheral tissues is relatively well 
understood, little is known about the effects of insulin on brain metabolism as the brain was 
originally thought to be insulin independent in this regard.8, 31 Despite the fact that insulin 
receptors have been found on the endothelium of the blood brain barrier, hypothalamus, cortex, 
cerebellum, amygdala, olfactory bulb, and hippocampus, and studies have shown that insulin 
does indeed penetrate the CSF and spread globally throughout the CNS, data from PET scans 
indicate that increasing insulin levels does not increase the uptake of glucose in the brain.8, 31 But 
if this is the case and insulin resistance plays no role in the pathogenesis of DM, why is it that 
those with Alzheimer’s disease have greater insulin resistance and are at a higher risk of 
developing DM, and why is that those with DM are 1.2 to 1.7 times more likely to acquire 
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Alzheimer’s disease?8 The studies performed on these correlations actually suggest the same or a 
similar pathogenesis between the development of these two diseases, and the root lies in insulin 
resistance.8 Those with Alzheimer’s seem to actually secrete more insulin in response to a 
glycemic load, and this “desensitization of neuronal insulin receptors” is what is believed to 
contribute to the development of sporadic Alzheimer’s disease in diabetics.8 
Other observations have been noted to exist in both diabetics and those with Alzheimer’s 
that may lead scientists and clinicians closer to the cause of cognitive impairment in these 
patients. First is the increased prevalence of inflammatory markers such as IL-6, C-reactive 
protein, and α-1-antichymotrypsin in any patient with insulin resistance.8 The second observation 
was disturbance of the hypothalamic-pituitary adrenal axis leading to excess levels of cortisol, 
which correlated to poorer memory performance and damaging structural changes in the 
hippocampus.8 The last observation was that DM patients had increased formation of senile 
plaques commonly found in Alzheimer’s patients, which are the result of cleavage of amyloid 
precursor protein in neurons into β-amyloid.8 Insulin-degrading enzyme is typically responsible 
for the breakdown of APP and β-amyloid, and is up-regulated by the presence of insulin.8 
However in an insulin resistant environment, higher glucose levels result in AGEing, and the 
enzyme instead binds to RAGEs (Receptor for Advanced Glycated End Products); the plaques 
are allowed to accumulate, thus bringing about glial and neuronal dysfunction.8 
Cardiovascular Neuropathy and the CNS 
 According to the Toronto Consensus Panel on Diabetic Neuropathy, sudden cardiac death 
is two to four times more likely in type 2 diabetics than any other subset of the population.32 
What is even more surprising is that this alarming statistic is not the product of accumulated 
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comorbidities that usually present with diabetes, but rather SCD is more prevalent because of 
cardiovascular autonomic neuropathy, a term assigned to “the impairment of cardiovascular 
autonomic control in the setting of diabetes after the exclusion of other causes.”32 Present in 
about 20% of the diabetic population, its prevalence can increase, depending on the duration of 
diabetes and age, to 65%. 32 
 CAN is characterized by damage to the autonomic nerves that provide innervation to the 
blood vessels and heart.33 Because the ANS is primarily responsible for regulating heart rate 
variability and cardiac performance, damage to these nerves manifests as silent myocardial 
infarction, intraoperative cardiovascular liability, exercise intolerance, orthostatic hypotension, 
and resting tachycardia.33, 34 All of these classic signs are linked to neuropathy that begins 
peripherally and works its way proximally.34 Moreover, because neuropathy affects longer 
nerves first, the vagus nerve is affected almost immediately and parasympathetic activity is 
severely down-regulated, as the tenth cranial nerve is normally responsible for 75% of 
parasympathetic function.34 
 Underlying all these clinical manifestations is a distinct inability of the body to interpret 
sensory stimuli and respond appropriately. With regards to exercise intolerance, for example, 
autonomic dysfunction minimizes the normal rise in blood pressure and heart rate that would 
normally occur, thereby reducing cardiac output and the person’s ability to supply their more 
metabolically active tissues with oxygen.33 The tachycardia observed is from impairment of the 
vagus nerve, which results in sympathetic overactivation characterized by abnormal 
norepinephrine metabolism and signaling.32, 34 QTi prolongation is also present, which is 
quantified as the delay in ventricular repolarization, and could be the reason why type I diabetics 
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suffer from arrhythmias and are more prone to the ‘dead in bed’ syndrome.32 Such cardiac 
rhythm disturbances are thought to be the result of electrolytic myocardial changes, as well as 
imbalances in sympathetic innervation.32 Orthostatic hypotension is thought to be the result of a 
reduction in the norepinephrine response that is proper for a relative drop in blood pressure, and 
would indicate a defect in the “centrally mediated” baroreflex.33 Reduction in the ventilator drive 
induced by hypoxia has also been observed in diabetic patients with CAN.33 Even in sleep, blood 
pressure variations based on circadian rhythms are improperly regulated, resulting in nocturnal 
hypertension.32, 34 
 Although neuropathy is often a complication of diabetes mellitus and plays a role in 
much of the cardiovascular dysfunction observed in the diabetic population, the decreased 
effectiveness of certain cardiac and respiratory reflexes would suggest that diabetes might have a 
detrimental effect on heart rate variability via central influences as well. A study conducted on 
STZ-injected rats revealed that they had decreased sensitivity to neuropeptide Y, which led them 
to conclude that chronic diabetes results in a decrease in the sensitivity of NTS neurons to certain 
neurotransmitters, and as a result sensory stimuli.35 In addition, diabetes may also influence the 
neurotransmitter metabolism.2 One circulating hypothesis is that cardiovascular autonomic 
neuropathy is instigated by the “dysregulation of neuropeptides, such as calcitonin gene-related 
peptide (CGRP) and vasoactive intestinal peptide (VIP)” and is characterized by prolongation of 
the interval of ventricular depolarization and repolarization.36 The cause seems to be irregular 
plasma levels of CGRP, ANP, VIP, NPY, and SP, whose vasomodulatory effects are what 
maintain cardiovascular homeostasis.36 Thus there exists a potential mechanism stemming from 
the central nervous system by which diabetes mellitus might influence cardiovascular function. 
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Effects of Diabetes Mellitus on Neurogenesis 
 Neurogenesis is defined as the process by which progenitor cells of the brain differentiate 
and becoming integrated on a functional level in the adult brain.37 After development of the 
mammalian brain in utero, this plasticity becomes limited to a few defined regions, such as the 
dentate gyrus of the hippocampus and the subventricular zone of the lateral ventricles, while the 
rest of the cerebral cortex is limited to neurogenic-to-astrogenic transformations.38, 39 In the 
subgranular zone of the DG, for example, progenitor cells proliferate and then travel to the 
granular cell layer.38 The stimulus for a plastic event usually stems from the environment, or a 
multiplicity of factors involving stress, pathological situations, aging, hormones, 
neurotransmitters, growth factors, neurodegeneration, or inflammation.37 Neural progenitor 
proliferation is consequently induced by a large multitude of transcription factors that are able to 
“sense” these changes and appropriate the proper physiological response, and often the 
production of these new hippocampal neurons is associated with memory formation and 
learning.37, 38, 39 With regards to differentiation, it is surprising to note that most newly generated 
neurons actually do not survive even in a normal physiological state, making the integration of 
those that do survive of even greater importance.37 Moreover, because the addition of new 
neurons in response to external and internal stimuli is purposed to optimize the communication 
between the CA3 pyramidal subfield and the dentate gyrus, any changes to the process of 
neurogenesis itself could influence and potentially interfere with the functions of this brain 
region.38  
 In diabetes, the state of the brain is not favorable towards the normal process of 
neurogenesis, and according to the literature, hippocampal alterations occur long before diabetes 
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clinically manifests, as early as the pre-diabetic state.37 In NOD mice, for example, there was a 
50% decrease in the rate of cell survival in the dentate gyrus, an overall low level of 
proliferation, and hippocampal astrogliosis was also observed.37, 38 These pathological signs are 
normally descriptors of aging and stress-induced depression, but unfortunately are not the only 
features of premature decline in diabetics.37, 38 In addition to early astrogliosis and low DG 
neuron count, increased levels of microglia indicative of ongoing inflammation are often present, 
in addition to greater expression of immune response genes, cytokines, and cytokine receptors.37 
This inflammation is detrimental for neurogenesis in the hippocampus and has also been 
implicated in the progression of Alzheimer’s disease and depression.37  
 Alterations in the structure of the diabetic hippocampus have also been correlated to the 
presence of the neuromarker apolipoprotein-E, which is normally a sign of neuronal 
dysfunction.40 Typically, this protein enters neurons when the cell is undergoing repair following 
some form of insult or injury, and is expressed by ependymal cells, astrocytes, and 
oligodendrocytes.40 Apo-E is thought to facilitate the removal of cellular debris because when 
the gene encoding it is mutated, the products of degeneration remain in the hippocampal cells.40 
Moreover, the worse the hippocampal injury, the greater the intensity of Apo-E expression in 
neurons that are degenerating, and most especially in the pyramidal neurons of CA1 and CA3.40 
Considered to have a neurotrophic role involved in learning and neuroplasticity, Apo-E 
expression has been linked to an attempt by the body to counter the progression of 
neurodegeneration.40 In addition, there is abnormal expression of the genes coding for proteins 
that would normally induce neuronal activation, such as Jun+ in the DG, CA1, and CA3 
regions.40 
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 One of the main reasons why diabetes is detrimental to the brain state, and more 
specifically hippocampal neurogenesis, is because diabetes is a metabolic stress.  Although stress 
would normally induce neuroplasticity in order to invoke adaptation to the stimuli, prolonged 
exposure actually instead produces an interminable burden resulting in allostatic overload.41 
Consequently, there is an increase in the expression of hypothalamic hormones, which in turn 
lead to overactivation of the hypothalamo-pituitary-adrenal axis (increasing cortisol levels) and 
an elevation in the sensitivity of the brain to stress.38, 40 Moreover because the hippocampus is 
rich in glucocorticoid receptors, and because glucocorticoids regulate hippocampal neurogenesis 
negatively, the result is a decreased number of new neurons in the dentate gyrus.37, 38 Other 
effects of this metabolic stressor include increased expression of apoptosis markers in the 
hippocampus, as well as reductions in the expression of synaptic proteins and dendritic spines.41 
Because dendrites actually comprise 95% of the total neuronal volume, this would account for 
why diabetics have reduced hippocampal volumes.41 
 Current studies have made an association not only between diabetes and 
neurodegenerative diseases such as Alzheimer’s, but depression as well.37 Epidemiological 
studies reveal that depression occurs at a rate of 12% in the type I diabetic population versus 
3.2% in the non-diabetic population, and 19.1% in type II diabetics versus the general 
populace.41 This reveals an interesting relationship between the comorbidities, which is 
reciprocal in the sense that diabetes increases the chance of suffering from depression and 
depression increases the likelihood of diabetes.41 Although poor self-care and lack of medical 
adherence may be at the root of this issue, insulin resistance in the brain is a more likely culprit 
as the link between the acquisition of depression and diabetes.41 As a result of hyperinsulinemia, 
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there are alterations in the levels of dopamine and serotonin in the CNS, as well as 
neurotrophins.41 Moreover, studies performed on animal models of depression and diabetes 
showed defective and reduced neurogenesis in the dentate gyrus, with decreases in hippocampal 
cell proliferation as large as 56% in comparison to the 27% decrease in diabetic rodents without 
depression.37, 41 Neuronal differentiation also suffered a decline in depressed diabetic rats by a 
difference of 17%, and cell survival was diminished by 44% in comparison to the diabetic 
model, which only suffered a 15% decrease in survival.41 Researchers therefore made the claim 
that depression occurs as a result of a decline in hippocampal neurogenesis below a certain 
threshold.41 Because diabetes interferes with neurogenesis in the brain, a subset of the diabetic 
population will reach and pass that threshold, resulting in depressive behavior.41 In support of 
this conclusion, treatment with antidepressant medications actually restores neurogenesis in the 
hippocampus to some degree.37 
 A newer area of study involving the effects of cognition and behavior, and to which the 
effects of diabetes would be interesting to explore, is related to another area of neurogenesis, the 
olfactory bulb. Although more crucial to the behavior of animals such as mice, in the mammalian 
brain in general, progenitor neuronal cells are known to travel from the subventricular zone to 
the olfactory bulb via the rostral migratory stream.20 Once there, these stem cells become 
inhibitory interneurons through the process of differentiation.20 In a study involving a mutated 
erk5 gene, a sequence which codes for the signaling protein EPK5 that helps to regulate 
neurogenesis in the SVZ-RMS-OB axis, researchers observed that the mice had reduced short-
term memory for certain odors, insensitivity with regards to odor detection, and deficits in 
olfactory-dependent behaviors.20 This finding has great significance in that many 
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neurodegenerative diseases, injuries, and even ordinary aging are linked to impairment in 
olfaction.20 It would therefore be considerable if a strategy was developed by which the decline 
in olfactory function could be halted and potentially mitigated in order to restore olfactory-linked 
functions in behavior and memory.20 
Implications for Current and Future Treatments 
 Although current treatments have managed to extend the length and quality of the lives of 
diabetic patients by reducing the incidence of complications, it has not been sufficient to wholly 
prevent its toll on their peripheral nerves, hearts, eyes, vasculature, and kidneys.21 Some studies 
have even suggested that current treatments may be the very cause of cognitive dysfunction and 
the increased prevalence of dementia in older diabetic patients.7  
 The first concern is that tighter glycemic control increases the prevalence and severity of 
hypoglycemic episodes, which have been previously implicated as the cause of decreased 
cognitive ability in diabetics. Occurring as often as 30 times per year, these events are 
characterized by malaise, hunger, anxiety, diaphoresis, and tremors, and the more often they 
occur the more likely the patient is to acquire hypoglycemia unawareness.42 Blunting of the 
counterregulatory response to hypoglycemia can in turn lead to neuroglycopenia characterized 
by confusion and seizures, and persistent hypoglycemia is associated with a torrent of 
sympathetic activity via the release of catecholamines.42 The resulting hemodynamic changes are 
thought to precipitate events of cerebral ischemia, and it is that reduced blood flow that could be 
the very mechanism for neurodegeneration on a regional and global level in the diabetic brain.42 
There are, however, two sides to this concept. Though diabetic patients from epidemiological 
studies in an ambulatory setting did have a higher risk of cerebrovascular events if they had a 
 51 
prior history of hypoglycemia, those that chose to participate in an intensive insulin therapy 
group and were consequently more prone to hypoglycemia did not.42 Therefore, it may be 
concluded that the cardioprotective benefits of these more intensive therapies outweigh the 
effects of hypoglycemia.32, 42 
Other studies have posed that insulin itself, and not hypoglycemia, is the culprit of “age-
related memory decline and diabetic encephalopathy.”7 Though once thought incapable of 
crossing the blood brain barrier (with the brain itself considered an insulin-independent organ) 
this hormone has been found in abundance in the hypothalamus and olfactory bulb, and its 
receptors have been found in the hippocampus and limbic system as well.7 Researchers postulate 
that insulin enables a gradual amassment of oxidized proteins by competitively inhibiting the 
role of insulin-degrading enzyme in protein turnover.7 Moreover, insulin actually inactivates a 
family of transcription factors that would normally allow the expression of genes responsible for 
defending against oxidative stress.7 This has been correlated to the observation that of the 
population suffering from type 2 diabetes, those undergoing insulin therapy have the greatest risk 
of developing dementia.7 
Furthermore, although most studies indicate that insulin is beneficial in the CNS because 
it increases the activity of insulin-degrading enzyme, which is responsible for the breakdown of 
senile amyloid plaques, others have suggested that insulin decreases intracellular levels of β-
amyloid by facilitating its secretion.8 This would raise levels of extracellular β-amyloid, which is 
allegedly responsible for memory loss and the development of Alzheimer’s disease.8 Such 
conflicting results foster a greater sense of urgency for research in this field, so that the causative 
agents of cognitive decline do not turn out to be rooted in present-day treatments. 
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 According to the literature, some of the findings related to macrostructural brain changes 
and their related pathological mechanisms suggest possible avenues in and of themselves for 
ameliorating the progression and severity of cognitive decline. The study that discovered that 
brain glucose metabolism in type 2 diabetics is more widespread regionally than in their 
nondiabetic counterparts, for example, found that increasing metabolism in the normally 
activated regions resulted in better performance on memory tests.22 Moreover, a reduction in the 
modifiable vascular risk factors thought to be associated with the development of Alzheimer’s 
and VaD would decrease the likelihood of such pathological states manifesting in older diabetics, 
especially if treated prior to the development of clinically significant cerebrovascular disease.22 
These forms of secondary prevention would also reduce the risk of strokes and cardiovascular 
disease, and improve recovery rates in diabetics, a subset of the population in which risks are 
already higher than normal and rehabilitation outcomes less than satisfactory.8, 22 
 Such an emphasis has been placed on increasing the foundational understanding of 
diabetes mellitus and its neurophysiologic and structural effects on the brain because with 
regards to quality of life and functional ability in the elderly, cognition plays an important role.22 
With its decline comes an actual decreased response to treatments for various medical 
conditions; therefore better comprehension of the progression, pathophysiology, and risk factors 
that accentuate these cognitive defects will allow healthcare providers and patients to take 
advantage of earlier windows of opportunity where medical interventions will prove most 
effective.22 
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APPENDIX A: ABREVIATIONS 
AMPA: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid  
Apo-E: Apolipoprotein E 
CA1: Cornu Ammonis area 1 
CA2: Cornu Ammonis area 2 
CA3: Cornu Ammonis area 3 
CAN: Cardiovascular Autonomic Neuropathy 
CBF: Cerebral Blood Flow 
CNS: Central Nervous System 
CSF: Cerebrospinal Fluid 
CT: Computed Tomography 
DG: Dentate Gyrus 
DM: Diabetes Mellitus 
EEG: Electroencephalogram 
FVB: Friend Virus B (Non-diabetic transgenic mouse model) 
GM: Gray matter 
HbA1c: Glycated hemoglobin 
LTD: Long Term Depression 
LTP: Long Term Potentiation 
MI: Myocardial Infarction 
MRI: Magnetic Resonance Imaging 
NMDA: N-methyl-D-aspartate 
OB: Olfactory Bulb 
OVE26: Transgenic type I diabetic mouse model 
PET: Positron Emission Tomography 
RAGE: Receptor for advanced glycated end products 
RMS: Rostral Migratory Stream 
ROS: Reactive Oxygen Species 
SCD: Sudden Cardiac Death 
SOD: Superoxide Dismutase 
STZ: Streptozotocin 
SVZ: Subventricular Zone 
WM: White matter 
 
 54 
APPENDIX B: SOLUTIONS FOR IMMUNOHISTOCHEMISTRY 
BSA Stock, 0.04 g/mL (50 mL) 
 2 g BSA (Bovine Serum Albumin) powder 
 Bring to 50 mL with PBS in  50 mL conical tube 
 Mix well by vortexing 
 
Triton X 100 (TX-100) Stock (50 μL/mL, 50 mL) 
 2.5 mL TX-100 
 Bring to 50 mL with PBS in 50 mL conical 
 Mix well by vortexing 
 
Sodium Azide (NaNH3) Stock, 8 mg/mL (10 mL) 
 Bring 80 mg (0.08g) sodium azide to 10 mL PBS in 15 mL conical tube. 
 Mix well by vortexing 
 
10X PBST, 30 ul/mL TX-100 (50 mL) 
 1.5 mL TX-100 to 50 mL PBS  
 Mix completely by vortexing 
 
PBS-T, 3 uL/mL TX-100 (50 mL) 
 5 mL 10 PBS-T 
 Bring to 50 mL in PBS 
 
Blocking Solution (15 mL) 
 3.750 mL PBS Buffer   
 7.500 mL BSA Stock        
 0.750 mL Normal Donkey Sera  
 1.500 mL NaNH3 Stock.  
 
Primary Antibody, 1ug/mL (1.5 mL) 
 0.480 mL PBS Buffer 
 0.750 mL BSA Stock 
 0.090 mL TX-100 Stock 
 0.030 mL Normal Donkey Sera 
 0.150 mL NaNH3 Stock 
 0.015 mL Primary Antibody [Abcam Rabbit Polyclonal anti-musashi1 antibody (ab21628, 
Lot# GR 72252-1), 100ug/mL] 
 
Secondary Antibody (1:500) 
 1.5 mL PBS-T 
 3 μL Secondary Antibody [Alexafluor Donkey Anti-Rabbit (a21207, Lot# 421207), 2 μg/mL] 
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